Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carfilzomib, Lenalidomide, and Dexamethasone in R/R MCL
NCT03891355Phase 2Unknown
- Sponsor
- Fondazione Italiana Linfomi
- Start
- Sep 2019
- Primary completion
- Dec 2020
- Modality
- Irreversible Covalent Inhibitors, Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of carfilzomib in mantle cell lymphoma (MCL), sponsored by Fondazione Italiana Linfomi. Primary endpoint: Overall Survival at 12 months. Status: unknown.
02
Drugs
carfilzomib
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT03891355.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03891355.